Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4results about How to "Reduce degeneration" patented technology

Joint implant for orthopedics department

The utility model belongs to the technical field of medical instruments, and relates to a joint implant for the orthopedics department. The joint implant is used for joint bone cartilage injury and defect repair and comprises a joint implant base body with a porous titanium structure and a top solid self-lubricating film. The joint implant base includes a top region, an upper region, and a lower region. The top area is matched with the outer contour face of the human body bone and is of a dense mirror face structure, the surface of the top area is plated with a solid self-lubricating film, abrasion to the opposite-side cartilage can be reduced to a large extent, and degeneration of the opposite-side cartilage is reduced. The side faces of the top area and the upper area of the joint implant base body make contact with subchondral bones and cancellous bones of the human body, and the lower area of the joint implant base body makes contact with the cancellous bones of the human body. The aperture and porosity of the joint implant base body extend from the upper area to the lower area, are increased in a gradient manner, are matched with the mechanical properties of human bones, and are beneficial to initial stability, early-stage rapid bone ingrowth and long-term stability.
Owner:ZHONGAO HUICHENG TECH CO LTD +1

Application of a Cav3.2 inhibitor in the preparation of drugs for treating intervertebral disc degeneration

This invention discloses the application of a Cav3.2 inhibitor in the preparation of a drug for treating intervertebral disc degeneration. Z944 can block the activation level of Cav3.2 in nucleus pulposus cells, effectively alleviating lipid metabolism disorders and cellular biological behavior disorders induced by abnormal mechanical stress, and ultimately reducing intervertebral disc degeneration. This demonstrates that Z944 is a drug with clinical application potential, which can be used to alleviate the pain and burden of patients with low back pain and improve their quality of life.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

A nanocomposite hydrogel for treating osteoarthritis and a preparation method and application thereof

PendingCN122499098Aavoid damagereduce degeneration
The application discloses a kind of nanocomposite hydrogel for treating osteoarthritis and its preparation method and application, the nanocomposite hydrogel includes cerium dioxide nanoparticles, the cerium dioxide nanoparticles are modified with hyaluronic acid;Ergothioneine is loaded on hyaluronic acid modified cerium dioxide nanoparticles to form nanocomposite EGT-CeO2@HA;And temperature-sensitive hydrogel carrier, the nanocomposite EGT-CeO2@HA is uniformly dispersed in the temperature-sensitive hydrogel carrier.This composite hydrogel can activate ATF4-dependent pro-survival autophagy pathway, reduce cartilage cell inflammatory damage, and improve cartilage degeneration.
Owner:THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV

Application of PAX8 gene inhibitors in the preparation of drugs for treating optic nerve degeneration

PendingCN122075517Areduce degenerationAchieve selective knockdownOrganic active ingredientsSenses disorderMedicineAxoplasmic transport
This invention belongs to the field of biomedical technology and relates to the application of PAX8 gene inhibitors in the preparation of drugs for treating optic nerve degeneration. The PAX8 gene inhibitor is a shRNA that targets and inhibits the PAX8 gene or a vector expressing a shRNA that targets and inhibits the PAX8 gene. The vector uses the astrocyte-specific promoter gfabc1d. Experiments have demonstrated that by specifically inhibiting PAX8 expression in astrocytes, axoplasmic transport obstruction in the optic nerve is relieved, optic nerve degeneration is alleviated, and a new gene therapy strategy is provided for the protective treatment of optic nerve degeneration in glaucoma.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV